MBX Biosciences, Inc. Depreciation
MBX Biosciences, Inc. (MBX) reported Depreciation of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- MBX Biosciences, Inc. depreciation for the quarter ending 2026-06-30 was $100.00K, a 0.00% change year-over-year.
- MBX Biosciences, Inc. depreciation for the quarter ending 2026-03-31 was $64.00K, a 16.88% decline year-over-year.
- MBX Biosciences, Inc. depreciation for the quarter ending 2025-12-31 was $60.00K, a 3.45% increase year-over-year.
- MBX Biosciences, Inc. depreciation for the quarter ending 2025-09-30 was $100.00K, a 0.00% change year-over-year.
- MBX Biosciences, Inc. depreciation for fiscal 2025 was $248.00K, a 1.64% increase from fiscal 2024.
- MBX Biosciences, Inc. depreciation for fiscal 2024 was $244.00K, a 55.41% increase from fiscal 2023.
- MBX Biosciences, Inc. depreciation for fiscal 2023 was $157.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-06 | $143.00K 10-Q · filed 2026-08-06 | $224.00K derived: sum of 3 quarters · filed 2026-08-06 | $324.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $64.00K 10-Q · filed 2026-05-07 | $124.00K derived: sum of 2 quarters · filed 2026-05-07 | $224.00K derived: sum of 3 quarters · filed 2026-05-07 | $324.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $160.00K derived: sum of 2 quarters · filed 2026-03-12 | $260.00K derived: sum of 3 quarters · filed 2026-08-06 | $248.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-06 | $200.00K derived: sum of 2 quarters · filed 2026-08-06 | $188.00K 10-Q · filed 2025-11-06 | $335.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-06 | $138.00K 10-Q · filed 2026-08-06 | $235.00K derived: sum of 3 quarters · filed 2026-08-06 | $335.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $77.00K 10-Q · filed 2026-05-07 | $135.00K derived: sum of 2 quarters · filed 2026-05-07 | $235.00K derived: sum of 3 quarters · filed 2026-05-07 | $335.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $158.00K derived: sum of 2 quarters · filed 2026-03-12 | $258.00K derived: sum of 3 quarters · filed 2026-03-12 | $244.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-06 | $200.00K derived: sum of 2 quarters · filed 2025-11-06 | $186.00K 10-Q · filed 2025-11-06 | $289.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-07 | $111.00K 10-Q · filed 2025-08-07 | $189.00K derived: sum of 3 quarters · filed 2025-08-07 | $289.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $48.00K 10-Q · filed 2025-05-12 | $89.00K derived: sum of 2 quarters · filed 2025-05-12 | $189.00K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $141.00K derived: sum of 2 quarters · filed 2025-03-17 | $157.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-07 | $116.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |